Phase 2 N=68 Hypofractionated Stereotactic Body Radiation Therapy (SBRT)
Prostate Cancer
Primary: Percentage of Patients With a Minimally Detected Decline (MDD) in Quality of Life (QOL) — 17; 18; 41; 19 percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=2 Washington Study of Hemofiltration After Out-of-Hospital Cardiac Arrest
Cardiac Arrest
Primary: Intervention Compliance — 1 participants
Phase 2 N=40 Implications for Treatment of the Metabolic Syndrome
Metabolic Syndrome
Primary: Muscle Microvascular Function — 3.7; 4.0 10^3 mL*min^-1*100ml^-1*mmHg^-1
Phase 2 N=54 Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions
Lupus Erythematosus, Discoid · Lupus Erythematosus, Systemic
Primary: Decrease in the Total Combined Erythema and Scaling Score (Minimum of 0 and Maximum of 65) of All Treated Lesions. — 22.2; 27.8 percentage of subjects
Phase 2 N=210 Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours
Non Small Cell Lung Cancer
Primary: Objective Response Rate (ORR) — 70.9 % of participants
Phase 2 N=252 A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)
Anaemia
Primary: Summary of Hemoglobin (Hgb) Concentration at Week 24 — 10.20; 10.64; 10.03; 10.66 grams per deciliter
Phase 2 N=63 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Response Rate Defined as Complete or Partial Response as Assessed by RECIST Version 1.0 Criteria. — 38.1; 0 percentage of patients
Phase 2 N=16 Lenalidomide and High-Dose Melphalan
Myeloma · Stem Cell Transplantation
Primary: Maximum Tolerated Dose (MTD) of Lenalidomide — 100 mg/day
Phase 2 N=10 Acute Human Study: StimRouter for Peripheral Nerve Stimulation of Discrete Peripheral Nerves
Unilateral Carpal Tunnel Syndrome
Primary: Implant Success — 10 participants with successful implant
Phase 2 N=20 Pilot Study to Evaluate The Effectiveness And Safety Of Axiom Worldwide Drx9000™ Spinal Decompression System
Low Back Pain
Primary: Post-treatment Numerical Pain Intensity Rating Scale (VRS), Which is a Scale From 0-10 (0=no Pain, 10= Worst Pain) — 0 units on a scale — p=.0001
Phase 2 N=3 Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant
Stage I Multiple Myeloma · Stage II Multiple Myeloma · Stage III Multiple Myeloma
Primary: Proportion of Patients Experiencing a Stringent Complete Response (sCR) After 12 Cycles, 24 Months — 100; 0; 100 percentage of participants
Phase 2 N=97 Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer
Ovarian Neoplasms
Primary: Progression Free Survival (PFS) — 19; 20; 20 Participants — p=0.6604
Phase 2 N=30 Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma
Lymphoma
Primary: Overall Response Rate — 15; 4 participants
Phase 2 N=24 Effect of Gymnema Sylvestre on Metabolic Syndrome and Insulin
Metabolic Syndrome
Primary: Waist Circumference (WC) — 101; 96 cm — p=0.57
Phase 2 N=124 Tecemotide (L-BLP25) in Rectal Cancer
Rectal Cancer
Primary: Change From Baseline in Tumor Immune Response Evaluated by Immunohistochemical (IHC) Analysis of Tumor Infiltrating Lymphocytes (TILs) at Week 14 (Post-surgery) — 0.609…